Class
Undo See the current
NY batch Contact Us for an
Early Intro
Bioeutectics
Green Natural and Biodegradable Solvents
70 million liters of non-green solvents are being manufactured per day

Bioeutectics has developed a technology capable of revolutionizing today’s industrial processes by supplying the next generation of green solvents. The company’s non-toxic, biodegradable, and sustainable solvents use a combination of readily available plant by-products and eutectic technology. AI-enhanced green chemistry allows the customization of products for use in a variety of industries such as food, agrotech, personal care, cosmetics, and gas capture.

Tomas Silicaro, CEO
"We want to revolutionize the Solvent industry - turning it into a Natural, Sustainable, and Biodegradable one. We are convinced that we can make industries better and greener with our products"
Bioeutectics has raised $725,000 from SOSV IndieBio and angel investors
Bioeutectics
Tomas Silicaro, CEO
"We want to revolutionize the Solvent industry - turning it into a Natural, Sustainable, and Biodegradable one. We are convinced that we can make industries better and greener with our products"
Bioeutectics has raised $725,000 from SOSV IndieBio and angel investors
AIMA
Empowering menstruators to manage their pain with freedom and dignity
90% of menstruators describe their period pain as moderate to severe.

AIMA, a female-led team, is developing clinically tested CBD-derived products for personalized period pain management. Their first OTC product, OVY™, is a vaginal suppository directing targeted-CBD to reduce pain and inflammation safely and effectively.

Lanna Last, CEO
"Join us to close the gender pain gap and empower menstruators with freedom and dignity.”
AIMA has raised $600,700 from SOSV IndieBio and angel investors
AIMA
Lanna Last, CEO
"Join us to close the gender pain gap and empower menstruators with freedom and dignity.”
AIMA has raised $600,700 from SOSV IndieBio and angel investors
Atlantic Fish Co
Developing cultivated seafood to provide the world with delicious and sustainable protein
Seafood is the most widely-eaten animal protein in the world - 178M metric tons per year are harvested through fishing and aquaculture.

Atlantic Fish is using cellular agriculture technology to develop sustainable, cultivated seafood. We are focused on premium white flaky fish including halibut, flounder, snapper, and black sea bass. We have developed novel bioengineering techniques to immortalize our cell lines and adapt them to suspension in order to grow in bioreactors at scale.

Doug Grant, CEO
"We want to help build a world where animals are completely removed from the food supply system and people can enjoy abundant access to delicious meat and seafood."
Atlantic Fish Co has raised $525,000 from SOSV IndieBio and the Genesis Consortium
Atlantic Fish Co
Doug Grant, CEO
"We want to help build a world where animals are completely removed from the food supply system and people can enjoy abundant access to delicious meat and seafood."
Atlantic Fish Co has raised $525,000 from SOSV IndieBio and the Genesis Consortium
FluoSphera
Drug Discovery without animals
Animal models fail to predict 90% of adverse side effects. There is a strong need to develop relevant systems to better anticipate drug toxicity.

To successfully develop drugs, we need to precisely predict candidate drug metabolization, efficacy, and safety before clinical trials. FluoSphera integrates these three aspects with a systemic approach to better predict the effects of drugs before they reach the patient, thus reducing drug development failure. FluoSphera provides a more predictive alternative to animal experimentation using only human-derived tissues.

"We were quite disappointed by the lack of relevance of in vitro models. So we decided to create a new method, much more predictive, to improve drug discovery."
FluoSphera has raised $1,025,000 from SOSV IndieBio and angel investors
FluoSphera
"We were quite disappointed by the lack of relevance of in vitro models. So we decided to create a new method, much more predictive, to improve drug discovery."
FluoSphera has raised $1,025,000 from SOSV IndieBio and angel investors
BioFluff
The future of fashion is plant-based and biodegradable
20+ countries have either voted to ban fur farming, prohibited farming particular species, or introduced stricter regulations that effectively curtail the practice.

BioFluff is the world’s first completely plant-based fur targeting the luxury clothing market. Their fur is plastic-free, GMO-free, and vegan, sourced from organic renewable fiber plants – no pesticides, herbicides, insecticides, petrochemicals or unsustainable raw-oil derivatives are used.

Martin Stübler, CEO
"Reason number one, it's perceived as a luxury material. So margins are pretty good. And most importantly, reason number two, it's one of the most unnecessary causes for animal suffering."
BioFluff has raised $625,000 from SOSV IndieBio and angel investors
BioFluff
Martin Stübler, CEO
"Reason number one, it's perceived as a luxury material. So margins are pretty good. And most importantly, reason number two, it's one of the most unnecessary causes for animal suffering."
BioFluff has raised $625,000 from SOSV IndieBio and angel investors
Protogenix
Better, faster, more affordable Protein Production system

Developer of a platform technology designed to replace the Mammalian Cell System for manufacturing complex proteins and eliminate the carbon footprint of animal agriculture. The company offers a decentralized plug-and-play method that delivers high-yield production at greater speed and lower cost than existing methods, enabling food and pharmaceutical producers to access sustainably functional and safe protein ingredients.

"The science that lies behind Protogenix provides us with innovative approaches with which to address food insecurity on many levels. Reducing our reliance on animals will lower the carbon footprint associated with conventional food production."
Protogenix has raised $525,000 from SOSV IndieBio and the Genesis Consortium
Protogenix
"The science that lies behind Protogenix provides us with innovative approaches with which to address food insecurity on many levels. Reducing our reliance on animals will lower the carbon footprint associated with conventional food production."
Protogenix has raised $525,000 from SOSV IndieBio and the Genesis Consortium
Pneuma
Everything breathes
In the US alone, an estimated 11.3 million tons of textile waste – equivalent to 85% of all textiles – end up in landfills each year.

Pneuma is developing the next generation of sustainable materials – implementing the process of photosynthesis as a product feature. OXYA, their living and breathing textile, is seeded with microalgae that consume carbon dioxide and produce oxygen.

CEO Spas Kerimov
“Sustainability is the bare minimum for the next generation of materials.”
Pneuma has raised $715,000 from SOSV IndieBio and other investors
Pneuma
CEO Spas Kerimov
“Sustainability is the bare minimum for the next generation of materials.”
Pneuma has raised $715,000 from SOSV IndieBio and other investors
Vitarka Therapeutics
Targeting the undruggable
Almost 85% patients with late-stage cancers do not have treatment options.

Vitarka Therapeutics is a pre-clinical stage biotech focused on developing RNAi therapies using a proprietary non-viral delivery platform. The underlying technology utilizes pore-forming proteins for targeted, cytosolic delivery of RNA therapeutics. Vitarka Therapeutics believes it can unlock new targeted therapeutic approaches for cancer treatment.

Vineeta Tripathi, CEO
"Vitarka is revolutionizing intracellular drug delivery by developing a new tumor-targeted platform technology using pore-forming proteins. RNA therapeutics have the potential to target 90% of the druggable proteome and bring benefits to patients and their families."
Vitarka Therapeutics has raised $875,000 from SOSV IndieBio, angel investors, and non-dilutive funding
Vitarka Therapeutics
Vineeta Tripathi, CEO
"Vitarka is revolutionizing intracellular drug delivery by developing a new tumor-targeted platform technology using pore-forming proteins. RNA therapeutics have the potential to target 90% of the druggable proteome and bring benefits to patients and their families."
Vitarka Therapeutics has raised $875,000 from SOSV IndieBio, angel investors, and non-dilutive funding